The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

In men with localized, intermediate-risk prostate cancer, stereotactic body radiation therapy (SBRT) was associated with less toxicity at 2 years but a higher rate of biochemical failure at 3 years ...

This trial looked at intensity modulated radiotherapy to treat prostate cancer which was likely to spread to the lymph nodes in the pelvis. It was supported by Cancer Research UK. Researchers running ...